ELISA News and Research

RSS

Hamilton and Rhinostics Reinvent Rapid Swab-Based Sample Workflows from Collection to Processing

Hamilton Company and Rhinostics are combining their respective strengths to improve the speed and quality of nasal and nasopharyngeal sample workflows.

From Hamilton Process Analytics 28 Sep 2021

COVID-19 vaccination reduces risk and duration of SARS-CoV-2 infection

In a study conducted at the European Institute of Oncology, scientists have found that the risk and duration of SARS-CoV-2 infection reduced significantly after COVID-19 vaccination.

28 Sep 2021

Third COVID-19 mRNA vaccine booster dose indicated for myelofibrosis patients

A new study discusses the utility of a third booster dose in patients with myelofibrosis.

27 Sep 2021

Chronic COVID-19 and divergent variants of SARS-CoV-2

A new study discusses the isolation of two variants of concern (VOCs) from an immunocompromised COVID-19 patient.

27 Sep 2021

Hyperbranched polylysine nanopolymer as potential broad-spectrum antiviral against SARS-CoV-2

The findings from this study suggest that HPNs may inhibit viral replication and budding.

27 Sep 2021

Central obesity associated with poor outcomes for Black breast cancer survivors

Findings from a recent population based cohort study show that Black women diagnosed with breast cancer who also have central obesity, which means excess body fat in the abdominal area, were more likely to die from breast cancer or any other cause than similar women who didn't have central obesity.

24 Sep 2021

Inactivated egg-based Newcastle disease virus vaccine expressing SARS-CoV-2 spike protein

A new study presents initial results from a randomized, placebo-controlled phase 1/2 trial in Thailand.

24 Sep 2021

Human milk antibodies elicited by vaccination show reduced activity against SARS-CoV-2 VoCs

In a study recently published on the medRxiv* preprint server, scientists from Singapore have assessed the levels of IgA-specific anti-severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) antibodies in the breast milk of women recently immunized with the second dose of an mRNA-based coronavirus disease 2019 (COVID-19) vaccine.

24 Sep 2021

Effect of prior SARS-CoV-2 infection on post-vaccination SARS-CoV-2 spike IgG antibodies

Natural infection or vaccination against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) confer considerable protection against reinfection and reduce the risk of severe Coronavirus disease 2019 (COVID-19) outcomes.

24 Sep 2021

COVID-19 vaccination and lactation

A new study evaluates the presence of antibodies in breastmilk and the immune responses of lactating women after vaccination of the COVID-19 vaccine.

23 Sep 2021

Antibody kinetics in recovered COVID-19 patients

Researchers from Tel Aviv University have been examining the kinetics of antibodies in recovered COVID-19 patients.

23 Sep 2021

Researchers encourage longer dosing intervals for Pfizer-BioNTech’s COVID-19 vaccine

Researchers in Canada, Italy, and the United States have encouraged extending the interval time between two doses of Pfizer-BioNTech’s coronavirus disease 2019 (COVID-19) vaccine among individuals who have not previously been infected with severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2).

22 Sep 2021

Comparison of recombinant SARS-CoV-2 receptor binding domain produced in mammalian, insect, and bacterial cells

In a recent study, RBD produced in various cell types are characterized in-depth, comparing their applicability for future COVID-19 research.

21 Sep 2021

New cell-free antibody generation platform successfully creates neutralizing antibodies effective against SARS-CoV-2

Researchers from the Broad Institute of MIT and Harvard have created a cell-free nanobody engineering platform that can produce antibodies effectively and quickly.

21 Sep 2021

A novel FACS-based approach for SARS-CoV-2 serology

A recent study discusses a simple, sensitive, and quantitative serological test based on FACS assay to evaluate antibodies against SARS-CoV-2.

20 Sep 2021

SARS-CoV-2 antibody models describe differences between the kinetics of different antibodies

Researchers have created kinetic models of IgG and IgM anti-SARS-CoV-2 antibodies over 13.5 months following infection to understand long-lasting immunity better.

20 Sep 2021

Humoral and cellular response to COVID-19 vaccines in patients with IBD

A new study published in the preprint server medRxiv* aimed to evaluate the humoral and cellular response to COVID-19 vaccine in patients with IBD undergoing biologic or immunomodulatory therapy.

17 Sep 2021

Adenovirus-based nanoparticle vaccine elicits potent SARS-CoV-2 neutralizing antibody response

In a study available on the preprint server medRxiv*, researchers have created a vaccine designed to overcome issues associated with attenuated-virus vaccines.

17 Sep 2021

IL-1-Ra autoantibodies observed in high frequency in children with PIMS/MIS-C

Although severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection typically affects children only mildly, multisystem inflammatory syndrome in children (MIS-C) or pediatric inflammatory multisystem syndrome (PIMS) is a serious but rare complication occurring after infection.

16 Sep 2021

Therapeutic potential of clinical-grade ACE2 for blocking SARS-CoV-2 variants

According to new research by an international team of scientists, all SARS-CoV-2 variants, including variants of concern (VOC) Alpha, Beta, Gamma, and Delta, exhibit enhanced affinity toward recombinant human soluble ACE2.

16 Sep 2021

ELISA News and Research

Hamilton and Rhinostics Reinvent Rapid Swab-Based Sample Workflows from Collection to Processing

COVID-19 vaccination reduces risk and duration of SARS-CoV-2 infection

Third COVID-19 mRNA vaccine booster dose indicated for myelofibrosis patients

Chronic COVID-19 and divergent variants of SARS-CoV-2

Hyperbranched polylysine nanopolymer as potential broad-spectrum antiviral against SARS-CoV-2

Central obesity associated with poor outcomes for Black breast cancer survivors

Inactivated egg-based Newcastle disease virus vaccine expressing SARS-CoV-2 spike protein

Human milk antibodies elicited by vaccination show reduced activity against SARS-CoV-2 VoCs

Effect of prior SARS-CoV-2 infection on post-vaccination SARS-CoV-2 spike IgG antibodies

COVID-19 vaccination and lactation

Antibody kinetics in recovered COVID-19 patients

Researchers encourage longer dosing intervals for Pfizer-BioNTech’s COVID-19 vaccine

Comparison of recombinant SARS-CoV-2 receptor binding domain produced in mammalian, insect, and bacterial cells

New cell-free antibody generation platform successfully creates neutralizing antibodies effective against SARS-CoV-2

A novel FACS-based approach for SARS-CoV-2 serology

SARS-CoV-2 antibody models describe differences between the kinetics of different antibodies

Humoral and cellular response to COVID-19 vaccines in patients with IBD

Adenovirus-based nanoparticle vaccine elicits potent SARS-CoV-2 neutralizing antibody response

IL-1-Ra autoantibodies observed in high frequency in children with PIMS/MIS-C

Therapeutic potential of clinical-grade ACE2 for blocking SARS-CoV-2 variants

Advancing Intracellular Delivery with LumiPore®

How ELRIG Is Helping Mid-Career Scientists Navigate Leadership, Career Change and Redundancy

The role of UV-Vis in biopharma QC

Latest News